澳大利亚维多利亚州SAEFVIC免疫接种后不良事件自发报告药物警戒监测方案评价
该研究对澳大利亚维多利亚州整合临床服务的增强被动AEFI监测系统SAEFVIC进行2007至2014年回顾性结构化桌面评价,以评估其是否达成改善AEFI报告、提供信号检测及维持消费者信心三个既定目标。结果显示AEFI报告量增至三倍(IRR 3.04,95%CI 2.35-3.93),维多利亚州报告量居全国首位、人群报告率排名第三,增幅最大见于儿童;56.2%(95%CI 54.1-58.4)的报告记录了后续接种。结论认为SAEFVIC改善了AEFI监测并促进信号调查与验证。
要点
- SAEFVIC使AEFI报告量增至三倍(IRR 3.04,95%CI 2.35-3.93),儿童增幅最大。
- 56.2%(95%CI 54.1-58.4)的AEFI报告记录了后续疫苗接种。
- 信号检测依赖监测护士临床怀疑或既往疫苗特异性关注,系统整合临床服务。
核心结论
- SAEFVIC改善了AEFI监测,促进信号调查与验证,并支持消费者对免疫接种的信心。
- 该系统在全国推广有可能提升澳大利亚疫苗药物警戒的能力,尤其是通过数据一致性和辖区可比性。
研究设计与样本
- 对SAEFVIC于2007至2014年收到的AEFI报告进行回顾性结构化桌面评价。
- 依据系统既定目标(改善AEFI报告、提供AEFI信号检测、维持消费者对疫苗接种的信心)进行评价。
主要发现
- SAEFVIC启动以来AEFI报告量增至三倍(IRR 3.04,95%CI 2.35-3.93)。
- 维多利亚州AEFI报告量居全国首位,人群报告率排名全国第三。
- AEFI报告增幅最大见于儿童。
- 数据被用于调查潜在信号事件并为疫苗政策提供信息。
- 56.2%(95%CI 54.1-58.4)的报告记录了AEFI后的后续接种;报告AEFI的儿童中到期或逾期接种比例比一般人群高2.3%。
临床怎么用
- 依托整合临床服务的增强被动监测系统可提高AEFI报告量并支持信号调查。
- 应关注AEFI报告后后续接种的记录与儿童接种及时性。
局限性
- 信号检测依赖监测护士的临床怀疑或既往疫苗特异性关注。
- 为单辖区回顾性桌面评价,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Australia is traditionally an early adopter of vaccines, therefore comprehensive and effective post-licensure vaccine pharmacovigilance is critical to maintain confidence in immunisation, both nationally and internationally. With adverse event following immunisation (AEFI) surveillance the responsibility of Australian jurisdictions, Victoria operates an enhanced passive AEFI surveillance system integrated with clinical services, called 'SAEFVIC' (Surveillance of Adverse Events Following Vaccination In the Community). OBJECTIVE: The aim of this study was to evaluate Victoria's current AEFI surveillance system 'SAEFVIC' and inform ongoing quality improvement of vaccine pharmacovigilance in Victoria and Australia. METHODS: We conducted a retrospective structured desktop evaluation of AEFI reporting received by SAEFVIC from 2007 to 2014, to evaluate the system according to its stated objectives, i.e. to improve AEFI reporting; provide AEFI signal detection; and to maintain consumer confidence in vaccination. RESULTS: AEFI reporting has tripled since SAEFVIC commenced (incidence risk ratio [IRR] 3.04, 95% confidence interval [CI] 2.35-3.93), raising Victoria to be the lead jurisdiction by AEFI reporting volume and to rank third by population reporting rate nationally. The largest increase was observed in children. Data were utilised to investigate potential signal events and inform vaccine policy. Signal detection required clinical suspicion by surveillance nurses, or prior vaccine-specific concerns. Subsequent vaccination post-AEFI was documented for 56.2% (95% CI 54.1-58.4) of reports, and the proportion of children due or overdue for vaccination was 2.3% higher for those reporting AEFI compared with the general population. CONCLUSION: SAEFVIC has improved AEFI surveillance, facilitates signal investigation and validation, and supports consumer confidence in immunisation. Expansion of the system nationally has the potential to improve capacity and capability of vaccine pharmacovigilance, particularly through data consistency and jurisdictional comparability in Australia.
引用
- Clothier HJ, Crawford NW, Russell M, et al. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia. Drug Saf. 2017. PMID: 28342074. doi:10.1007/s40264-017-0520-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。